-
Bristol Myers Squibb announces acquisition of schizophrenia drug manufacturer Karuna for $14 billion
On December 22nd local time, Bristol Myers Squibb and Karuna Therapeutics announced that they had signed a final merger agreement. According to the agreement, Bristol Myers Squibb has agreed to acqui ... -
Johnson&Johnson Long acting Schizophrenic Therapy Approved in China
Johnson&Johnson's long-acting schizophrenia therapy has been approved in China. Johnson&Johnson announced that its long-acting injection, Shanjiuda, which is administered every six months, has recent ... -
Zaiding Medicine: Clinical study of KarXT for the treatment of schizophrenia completed, enrolled patients from mainland China
On August 13th, Zaiding Pharmaceutical announced that the UNITE-1 study of KarXT (Xanomeline Tropium) for schizophrenia has completed the enrollment of all mainland Chinese patients. Zaiding Pharmace ... -
How is the progress of the world's first new drug for schizophrenia approved in the US and in the Chinese market
On September 26th local time, the US Food and Drug Administration (FDA) announced the approval of BMS's schizophrenia drug Cobenfy (KarXT, xanomiline and trospium chloride) for the treatment of adult ...